

AUTHOR INDEX FOR VOLUME 29

A

- Adamik, R., *see* Halpern, J. L., 515
 Ahljianian, M. K., *see* Cooper, D. F., 113
 Ahmed, K., *see* Griffin, J. F., 270
 Albuquerque, E. X., *see* Swanson, K. L., 250
 Allan, A. M., and Harris, R. A. γ -Aminobutyric acid agonists and antagonists alter chloride flux across brain membranes, 497
 Allan, P. W., *see* Bennett, L. L., Jr., 383
 Allen, C. N., *see* Swanson, K. L., 250
 Alvarez, R., Banerjee, G. L., Bruno, J. J., Jones, G. L., Liitschwager, K., Strosberg, A. M., and Venuti, M. C. A potent and selective inhibitor of cyclic AMP phosphodiesterase with potential cardi-
 otonic and antithrombotic properties, 554
 Amar, S., *see* Bozou, J.-C., 489
 Antonello, C., *see* Palù, G., 211
 Anundi, I. M., Kauffman, F. C., El-Mouelhi, M., and Thurman, R. G.
 Hydrolysis of organic sulfates in periportal and pericentral regions
 of the liver lobule: Studies with 4-methylumbelliferyl sulfate in the
 perfused rat liver, 599
 Armstrong, R. D., *see* Takimoto, C. H., 637
 Aronstam, R. S., *see* Swanson, K. L., 250
 Asano, T., and Ogasawara, N. Uncoupling of aminobutyric acid B
 receptors from GTP-binding proteins by *N*-ethylmaleimide: effect
 of *N*-ethylmaleimide on purified GTP-binding proteins, 244
 Ashida, K., *see* Gono, T., 347

B

- Bachur, N. R., *see* Pan, S.-S., 622
 Baker, P. F., *see* Powis, D. A., 134
 Bali, J.-P., *see* Magous, R., 39
 Banerjee, G. L., *see* Alvarez, R., 554
 Barnett, G. Alteration of cytosine-guanine interactions due to N7 metal
 cation binding: A structure-activity relationship for cisplatin ana-
 logues, 378
 Beavo, J. A., *see* Harrison, S. A., 506
 Bekesi, E., *see* Halpern, J. L., 515
 Bend, J. R., *see* Horton, J. K., 484
 Bennett, L. L., Jr., Allan, P. W., Rose, L. M., Comber, R. N., and
 Sechrist, J. A., III. Differences in the metabolism and metabolic
 effects of the carbocyclic adenosine analogs, neplanocin A and
 aristeromycin, 383
 Bier-Laning, C. M., *see* Cooper, D. F., 113
 Bigelow, J., *see* Oswald, R. E., 179
 Black, K. A., *see* Tephly, T. R., 81
 Blackmore, P. F., *see* Lynch, C. J., 196
 Bocckino, S. B., *see* Brostrom, C. O., 104
 Bolger, M. B., *see* Sherman, M. A., 589
 Borowski, E., *see* Cybulska, B., 293
 Boyd, N. D., *see* Oblas, B., 649
 Bozou, J.-C., Amar, S., Vincent, J.-P., and Kitabgi, P. Neurotensin-
 mediated inhibition of cyclic AMP formation in neuroblastoma
 N1E115 cells: Involvement of the inhibitory GTP-binding com-
 ponent of adenylate cyclase, 489
 Brigelius, R., *see* Horton, J. K., 484
 Britt, M., Zunino, F., and Chaires, J. B. The interaction of the β -
 anomer of doxorubicin with B and Z DNA, 74
 Brostrom, C. O., Bocckino, S. B., Brostrom, M. A., and Galuska, E. M.
 Regulation of protein synthesis in isolated hepatocytes by calcium-
 mobilizing hormones, 104
 Brostrom, C. O., *see* Wolfe, S. E., 411

- Brostrom, M. A., *see* Brostrom, C. O., 104
 Brostrom, M. A., *see* Wolfe, S. E., 411, 420
 Brown, R. D., Prendiville, P., and Cain, C. α_1 -Adrenergic and H1-
 histamine receptor control of intracellular Ca^{2+} in a muscle cell
 line: The influence of prior agonist exposure on receptor respon-
 siveness, 531
 Bruno, J. J., *see* Alvarez, R., 554
 Bruns, R. F., Lu, G. H., and Pugsley, T. A. Characterization of the A_2
 adenosine receptor labeled by [3H]NECA in rat striatal mem-
 branes, 331
 Butt, T. R., Sternberg, E. J., Mirabelli, C. K., and Crooke, S. T.
 Regulation of metallothionein gene expression in mammalian cells
 by gold compounds, 204

C

- Cadd, G. G., *see* Harrison, S. A., 506
 Cadman, E. C., *see* Takimoto, C. H., 637
 Cain, C., *see* Brown, R. D., 531
 Calder, I., *see* Hayward, N. K., 478
 Campanile, C., *see* Wrighton, S. A., 405
 Cantoni, O., *see* Christie, N. T., 173
 Cantoni, O., *see* Sugiyama, M., 606
 Cascieri, M. A., Chicchi, G. G., Freidinger, R. M., Colton, C. D., and
 Perlow, D. S. Conformationally constrained tachykinin analogs
 which are selective ligands for the eledoisin binding site, 34
 Cashman, J. R., and Ziegler, D. M. Contribution of *N*-oxygenation to
 the metabolism of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydro-
 pyridine) by various liver preparations, 163
 Cattabeni, F., *see* Christie, N. T., 173
 Catterall, W. A., *see* Gono, T., 347
 Chaires, J. B., *see* Britt, M., 74
 Chicchi, G. G., *see* Cascieri, M. A., 34
 Christie, N. T., Cantoni, O., Sugiyama, M., Cattabeni, F., and Costa,
 M. Differences in the effects of Hg(II) on DNA repair induced in
 Chinese hamster ovary cells by ultraviolet or X-rays, 173
 Clark, M. A., *see* Mong, S., 235
 Coffman, B. L., *see* Tephly, T. R., 81
 Colton, C. D., *see* Cascieri, M. A., 34
 Comber, R. N., *see* Bennett, L. L., Jr., 383
 Conn, P. M., *see* McArdle, C. A., 570
 Cooper, D. F., Bier-Laning, C. M., Halford, M. K., Ahljianian, M. K.,
 and Zahniser, N. R. Dopamine, acting through D-2 receptors,
 inhibits rat striatal adenylate cyclase by a GTP-dependent process,
 113
 Coornaert, S., *see* Gasnier, B., 275
 Costa, M., *see* Christie, N. T., 173
 Costa, M., *see* Sugiyama, M., 606
 Couvineau, A., *see* Laburthe, M., 23
 Creese, I., *see* Morrow, A. L., 321
 Crooke, S. T., *see* Butt, T. R., 204
 Crooke, S. T., *see* Mong, S., 235
 Cybulska, B., Herve, M., Borowski, E., and Gary-Bobo, C. M. Effect of
 the polar head structure of polyene macrolide antifungal antibiotics
 on the mode of ergosterol- and cholesterol-containing lipidic vesi-
 cles studied by ^{31}P -NMR, 293

D

- Daly, J. W., *see* Jacobson, K. A., 126
 Dannan, G. A., *see* Tephly, T. R., 81
 Dempster, J., *see* Henderson, F., 52

- Desplanches, G., *see* Gasnier, B., 275
 Dickie, P., Morgan, A. R., Scraba, D. G., and von Borstel, R. C. The binding of the antihelminthic pyriminium cation to deoxyribonucleic acid *in vitro*, 427
 Dolnick, B. J., *see* Will, C. L., 643
- E**
- El-Mouelhi, M., *see* Anundi, I. M., 599
 Escale, R., *see* Magous, R., 39
 Exton, J. H., *see* Lynch, C. J., 196
- F**
- Feller, D., *see* Gonoï, T., 347
 Fernandes, K. G., *see* Lippiello, P. M., 448
 Ferry, N., *see* Motulsky, H. J., 1
 Fournie-Zaluski, M.-C., *see* Maigret, B., 314
 Foxall, D., *see* Matthews, P. M., 65
 Freidinger, R. M., *see* Cascieri, M. A., 34
 Frey, E. A., Kebabian, J. W., and Guild, S. Forskolin enhances calcium-evoked prolactin release from 7315c tumor cells without increasing the cytosolic calcium concentration, 461
 From, A. H. L., *see* Griffin, J. F., 270
 Fujiwara, M., *see* Gonoï, T., 347
 Fullerton, D. S., *see* Griffin, J. F., 270
- G**
- Gallis, B., *see* Harrison, S. A., 506
 Galuska, E. M., *see* Brostrom, C. O., 104
 Gary-Bobo, C. M., *see* Cybulska, B., 293
 Gasnier, B., Roisin, M.-P., Scherman, D., Coornaert, S., Desplanches, G., and Henry, J.-P. Uptake of *meta*-iodobenzylguanidine by bovine chromaffin granule membranes, 275
 Girard, J.-P., *see* Magous, R., 39
 Giros, B., Gros, C., Solhonne, B., and Schwartz, J.-C. Characterization of aminopeptidases responsible for inactivating endogenous (Met⁵)enkephalin in brain slices using peptidase inhibitors and antiaminopeptidase M antibodies, 281
 Gonoï, T., Ashida, K., Feller, D., Schmidt, J., Fujiwara, M., and Catterall, W. A. Mechanism of action of a polypeptide neurotoxin from the coral coniopora on sodium channels in mouse neuroblastoma cells, 347
 Graham, R. M., *see* Lanier, S. M., 219
 Green, M. D., *see* Tephly, T. R., 81
 Gresh, N., and Pullman, B. A theoretical study of the binding of phenothiazine derivatives to residues 82-93 of calmodulin, 355
 Griffin, J. F., Rohrer, D. C., Ahmed, K., From, A. H. L., Hashimoto, T., Rathore, H., and Fullerton, D. S. The effect of 16 β -substitution on the structure and activity of digitoxigenin: Is there an additional binding interaction with Na⁺K⁺-ATPase?, 270
 Grodski, A., *see* Lanier, S. M., 219
 Gros, C., *see* Giros, B., 281
 Guild, S., *see* Frey, E. A., 461
 Guzelian, P. S., *see* Wrighton, S. A., 405
- H**
- Hagiwara, M., *see* Inagaki, M., 577
 Halford, M. K., *see* Cooper, D. F., 113
 Halpern, J. L., Tsai, S.-C., Adamik, R., Kanaho, Y., Bekesi, E., Kung, H.-F., Moss, J., and Vaughan, M. Structural and functional characterization of guanyl nucleotide-binding proteins using monoclonal antibodies to the α -subunit of transducin, 515
 Halpert, J., *see* Miller, N. E., 391
 Haniu, M., *see* Wrighton, S. A., 405
 Hansch, C., *see* Recanatini, M., 436
 Harden, T. K., *see* Nakahata, N., 188
 Harden, T. K., *see* Tanner, L. I., 455
 Harris, C., and Thurman, R. G. A new method to study glutathione adduct formation in periportal and pericentral regions of the liver lobule by microreflectance spectrophotometry, 88
 Harris, R. A., *see* Allan, A. M., 497
 Harrison, S. A., Reifsnnyder, D. H., Gallis, B., Cadd, G. G., and Beavo, J. A. Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: A receptor for new cardiotonic drugs, 506
 Hartig, P. R., *see* Yagaloff, K. A., 120
 Hashimoto, T., *see* Griffin, J. F., 270
 Hayward, N. K., Calder, I., and Lavin, M. F. Effect of *N*-hydroxy-*para*-acetamol on DNA, RNA, and protein synthesis and chromatin structure, 478
 Heimbrown, D. C., and Sartorelli, A. C. Biochemistry of misonidazole reduction by NADPH-cytochrome c (P-450) reductase, 168
 Henderson, F., Prior, C., Dempster, J., and Marshall, I. G. The effects of chloramphenicol isomers on the motor end-plate nicotinic receptor-ion channel complex, 52
 Henry, J.-P., *see* Gasnier, B., 275
 Hepler, J. R., *see* Nakahata, N., 188
 Herve, M., *see* Cybulska, B., 293
 Hess, H.-J., *see* Lanier, S. M., 219
 Hidaka, H., *see* Inagaki, M., 577
 Hidaka, H., *see* Tanaka, T., 264
 Hinson, J. A., *see* Potter, D. W., 155
 Hnilica, L. S., 447
 Homcy, C. J., *see* Lanier, S. M., 219
 Horton, J. K., Brigelius, R., Mason, R. P., and Bend, J. R. Paraquat uptake into freshly isolated rabbit lung epithelial cells and its reduction to the paraquat radical under anaerobic conditions, 484
 Howlett, A. C., Quail, J. M., and Khachatryan, L. L. Involvement of G_i in the inhibition of adenylate cyclase by cannabimimetic drugs, 307
 Hughes, A. R., *see* Nakahata, N., 188
 Hughes, R. J., and Insel, P. A. Agonist-mediated regulation of α_1 - and β_2 -adrenergic receptor metabolism in a muscle cell line, BC3H-1, 521
- I**
- Inagaki, M., Kawamoto, S., Itoh, H., Saitoh, M., Hagiwara, M., Takahashi, J., and Hidaka, H. Naphthalenesulfonamides as calmodulin antagonists and protein kinase inhibitors, 577
 Insel, P. A., *see* Hughes, R. J., 521
 Insel, P. A., *see* Mahan, L. C., 7, 16
 Insel, P. A., *see* Motulsky, H. J., 1
 Iracki, T., *see* Pan, S.-S., 622
 Ishikawa, T., *see* Tanaka, T., 264
 Ito, M., *see* Tanaka, T., 264
 Itoh, H., *see* Inagaki, M., 577
 Itoh, H., *see* Tanaka, T., 264
- J**
- Jacobson, K. A., Kirk, K. L., Padgett, W. L., and Daly, J. W. A functionalized congener approach to adenosine receptor antagonists: Amino acid conjugates of 1,3-dipropylxanthine, 126
 Jakobs, K. H., *see* Watanabe, Y., 258
 Johnson, G. V. W., *see* Jope, R. S., 45
 Jones, G. L., *see* Alvarez, R., 554
 Jope, R. S., and Johnson, G. V. W. Quinacrine and 2-(4-phenylpiperidino)cyclohexanol (AH5183) inhibit acetylcholine release and synthesis in rat brain slices, 45
- K**
- Kamaya, H., *see* Mashimo, T., 149
 Kamaya, H., *see* Ueda, I., 582
 Kaminoh, Y., *see* Ueda, I., 582
 Kanaho, Y., *see* Halpern, J. L., 515
 Kauffman, F. C., *see* Anundi, I. M., 599
 Kawamatsu, Y., *see* Tanaka, T., 264

- Kawamoto, S., see Inagaki, M., 577
 Kebabian, J. W., see Frey, E. A., 461
 Keys, C., see Loew, G., 546
 Khachatrian, L. L., see Howlett, A. C., 307
 Kim, D., and Smith, T. W. Effects of amiloride and ouabain on contractile state, Ca and Na fluxes, and Na content in cultured chick heart cells, 363
 Kirk, K. L., see Jacobson, K. A., 126
 Kitabgi, P., see Bozou, J.-C., 489
 Klein, T., see Recanatini, M., 436
 Klotz, K.-N., see Lohse, M. J., 228
 Koop, D. R. Hydroxylation of *p*-nitrophenol by rabbit ethanol-inducible cytochrome P-450 isozyme 3A, 399
 Kuczenski, R., see Strait, K. A., 561
 Kung, H.-F., see Halpern, J. L., 515

L

- Laburthe, M., Couvineau, A., and Rouyer-Fessard, C. Study of species specificity in growth hormone-releasing factor (GRF) interaction with vasoactive intestinal peptide (VIP) receptors using GRF and VIP receptors from rat and human: Evidence that Ac-Tyr⁴hGRF is a competitive VIP antagonist in the rat, 23
 Langridge, R., see Recanatini, M., 436
 Lanier, S. M., Hess, H.-J., Grodski, A., Graham, R. M., and Homcy, C. J. Synthesis and characterization of a high affinity radioiodinated probe for the α_2 -adrenergic receptor, 219
 Larsen, G. L., and Stevens, J. L. Cysteine conjugate β -lyase in the gastrointestinal bacterium *Eubacterium limosum*, 97
 Larsson, A., Sundqvist, A., and Parnerud, A.-M. Inhibition of herpes simplex virus-induced DNA polymerase α by triphosphates of acyclic guanosine analogs, 614
 Lavin, M. F., see Hayward, N. K., 478
 Levin, W., see Wrighton, S. A., 405
 Lin, S. H., see Ueda, I., 582
 Linthicum, D. S., see Sherman, M. A., 589
 Lippiello, P. M., and Fernandes, K. G. The binding of L-[³H]nicotine to a single class of high affinity sites in rat brain membranes, 448
 Liittschwager, K., see Alvarez, R., 554
 Loew, G., Keys, C., Luke, B., Polgar, W., and Toll, L. Structure-activity studies of morphiceptin analogs: Receptor binding and molecular determinations of μ -affinity and selectivity, 546
 Lohse, M. J., Klotz, K.-N., and Schwabe, U. Effect of temperature and membrane phase transitions on ligand binding to α_2 -receptors of human platelets, 228
 Lu, G. H., see Bruns, R. F., 331
 Lueddens, H. W. M., Newman, A. H., Rice, K. C., and Skolnick, P. AHN 086: An irreversible ligand of "peripheral" benzodiazepine receptors, 540
 Luke, B., see Loew, G., 546
 Luster, M. I., see Tucker, A. N., 372
 Lynch, C. J., Prpic, V., Blackmore, P. F., and Exton, J. H. Effect of islet-activating pertussis toxin on the binding characteristics of Ca²⁺-mobilizing hormones and on agonist activation of phosphor-lyase in hepatocytes, 196

M

- Ma, S.-M., see Ueda, I., 582
 Magous, R., Bali, J.-P., Escalé, R., Girard, J.-P., Rechencq, E., and Rossi, J.-C. Evidence for the existence of high affinity binding sites for indomethacin on human blood platelets, 39
 Mahan, L. C., and Insel, P. A. Expression of β -adrenergic receptors in synchronous and asynchronous S49 lymphoma cells. I. Receptor metabolism after irreversible blockade of receptors and cells traversing the cell division cycle, 7
 Mahan, L. C., and Insel, P. A. Expression of β -adrenergic receptors in synchronous and asynchronous S49 lymphoma cells. II. Relationship between receptor number and response, 16
 Maigret, B., Fournie-Zaluski, M.-C., Roques, B., and Premilat, S.

- Proposals for the μ -active conformation of the enkephalin analog Tyr-cyclol(-N γ -D-A₂-bu-Gly-Phe-Leu-), 314
 Maines, S. L., see Wrighton, S. A., 405
 Mansour, T. E., see Matthews, P. M., 65
 Marciani-Magno, S., see Palù, G., 211
 Marshall, I. G., see Henderson, F., 52
 Martin, M. W., see Nakahata, N., 188
 Martin, M. W., see Tanner, L. I., 455
 Mashimo, T., Kamaya, H., and Ueda, I. Anesthetic-protein interaction: Surface potential of bovine serum albumin estimated by a pH-sensitive dye, 149
 Mason, R. P., see Horton, J. K., 484
 Matthews, P. M., Foxall, D., Shen, L., and Mansour, T. E. Nuclear magnetic resonance studies of carbohydrate metabolism and substrate cycling in *Fasciola hepatica*, 65
 Maynard, A. T., Pedersen, L. G., Posner, H. S., and McKinney, J. D. An *ab initio* study of the relationship between nitroarene mutagenicity and electron affinity, 629
 Mazurek, A. P., see Weinstein, H., 28
 McArdle, C. A., and Conn, P. M. Hormone-stimulated redistribution of gonadotropin protein kinase C *in vivo*: Dependence on Ca²⁺ influx, 570
 McClarin, J., see Recanatini, M., 436
 McKinney, J. D., see Maynard, A. T., 629
 Meloni, G. A., see Palù, G., 211
 Mendez-Picon, G., see Wrighton, S. A., 405
 Michel, L., see Oswald, R. E., 179
 Miller, D. W., see Potter, D. W., 155
 Miller, N. E., and Halpert, J. Analogues of chloramphenicol as mechanism-based inactivators of rat liver cytochrome P-450: Modifications of the propanediol side chain, the *p*-nitro group, and the dichloromethyl moiety, 391
 Mirabelli, C. K., see Butt, T. R., 204
 Mong, S., Wu, H.-L., Stadel, J. M., Clark, M. A., and Crooke, S. T. Solubilization of [³H]leukotriene D₄ receptor complex from guinea pig lung membranes, 235
 Morgan, A. R., see Dickie, P., 427
 Morrow, A. L., and Creese, I. Characterization of α_1 -adrenergic receptor subtypes in rat brain: A reevaluation of [³H]WB4101 and [³H]prazosin binding, 321
 Moss, J., see Halpern, J. L., 515
 Motulsky, H. J., Shattil, S. J., Ferry, N., Rozansky, D., and Insel, P. A. Desensitization of epinephrine-initiated platelet aggregation does not alter binding to the α_2 -adrenergic receptor or coupling to adenylate cyclase, 1

N

- Nakahata, N., Martin, M. W., Hughes, A. R., Hepler, J. R., and Harden, T. K. H₁-histamine receptors on human astrocytoma cells, 188
 Newman, A. H., see Lueddens, H. W. M., 540

O

- Oblas, B., Singer, R. H., and Boyd, N. D. Location of a polypeptide sequence within the α -subunit of the acetylcholine receptor containing the cholinergic binding site, 649
 Ogasawara, N., see Asano, T., 244
 Osman, R., see Weinstein, H., 28
 Oswald, R. E., Michel, L., and Bigelow, J. Mechanism of binding of a benzomorphan opiate to the acetylcholine receptor from *Torpedo* electroplaque, 179

P

- Padgett, W. L., see Jacobson, K. A., 126
 Palù, G., Palumbo, M., Antonello, C., Meloni, G. A., and Marciani-Magno, S. A search for potential antitumor agents: Biological effects and DNA binding of a series of anthraquinone derivatives, 211
 Palumbo, M., see Palù, G., 211

- Pan, S.-S., Iracki, T., and Bachur, N. R. DNA alkylation by enzyme-activated mitomycin C, 622
- Parker, G., *see* Wrighton, S. A., 405
- Parnerud, A.-M., *see* Larsson, A., 614
- Patierno, S. R., *see* Sugiyama, M., 606
- Pedersen, L. G., *see* Maynard, A. T., 629
- Perlow, D. S., *see* Cascieri, M. A., 34
- Polgar, W., *see* Loew, G., 546
- Posner, H. S., *see* Maynard, A. T., 629
- Potter, D. W., Miller, D. W., and Hinson, J. A. Horseradish peroxidase-catalyzed oxidation of acetaminophen to intermediates that form polymers or conjugate with glutathione, 155
- Powis, D. A., and Baker, P. F. α_2 -Adrenoceptors do not regulate catecholamine secretion by bovine adrenal medullary cells: A study with clonidine, 134
- Premilat, S., *see* Maigret, B., 314
- Prendiville, P., *see* Brown, R. D., 531
- Prior, C., *see* Henderson, F., 52
- Prpic, V., *see* Lynch, C. J., 196
- Pugsley, T. A., *see* Bruns, R. F., 331
- Pullman, B., *see* Gresh, N., 355
- Q**
- Qualy, J. M., *see* Howlett, A. C., 307
- R**
- Rando, T. A., Wang, G. K., and Strichartz, G. R. Interaction between the activator agents batrachotoxin and veratridine and the gating processes of neuronal sodium channels, 467
- Rapoport, H., *see* Swanson, K. L., 250
- Rathore, H., *see* Griffin, J. F., 270
- Recanatini, M., Klein, T., Yang, C.-Z., McClarin, J., Langridge, R., and Hansch, C. Quantitative structure-activity relationships and molecular graphics in ligand receptor interactions: Amidine inhibition of trypsin, 436
- Rechencq, E., *see* Magous, R., 39
- Reifsnnyder, D. H., *see* Harrison, S. A., 506
- Rice, K. C., *see* Lueddens, H. W. M., 540
- Rohrer, D. C., *see* Griffin, J. F., 270
- Roisin, M.-P., *see* Gasnier, B., 275
- Roques, B., *see* Maigret, B., 314
- Rose, L. M., *see* Bennett, L. L., Jr., 383
- Rossi, J.-C., *see* Magous, R., 39
- Rouyer-Fessard, C., *see* Laburthe, M., 23
- Rozansky, D., *see* Motulsky, H. J., 1
- S**
- Saitoh, M., *see* Inagaki, M., 577
- Saitoh, M., *see* Tanaka, T., 264
- Sartorelli, A. C., *see* Heimbrook, D. C., 168
- Scherman, D., *see* Gasnier, B., 275
- Schmidt, J., *see* Gonoï, T., 347
- Schwabe, U., *see* Lohse, M. J., 228
- Schwartz, J.-C., *see* Giros, B., 281
- Scraba, D. G., *see* Dickie, P., 427
- Secrist, J. A., III, *see* Bennett, L. L., Jr., 383
- Shattil, S. J., *see* Motulsky, H. J., 1
- Shen, L., *see* Matthews, P. M., 65
- Sherman, M. A., Linthicum, D. S., and Bolger, M. B. Haloperidol binding to monoclonal antibodies: Conformational analysis and relationships to D-2 receptor binding, 589
- Shin, T., *see* Tanaka, T., 264
- Shively, J. E., *see* Wrighton, S. A., 405
- Singer, R. H., *see* Oblas, B., 649
- Skolnick, P., *see* Lueddens, H. W. M., 540
- Smith, T. W., *see* Kim, D., 363
- Snyder, S. H., *see* Strittmatter, S. M., 142
- Solhonne, B., *see* Giros, B., 281
- Stadel, J. M., *see* Mong, S., 235
- Sternberg, E. J., *see* Butt, T. R., 204
- Stevens, J. L., *see* Larsen, G. L., 97
- Strait, K. A., and Kuczenski, R. Dopamine autoreceptor regulation of the kinetic state of striatal tyrosine hydroxylase, 561
- Strichartz, G. R., *see* Rando, T. A., 467
- Strittmatter, S. M., and Snyder, S. H. Characterization of angiotensin converting enzyme by [3 H]captopril binding, 142
- Strosberg, A. M., *see* Alvarez, R., 554
- Sugihara, H., *see* Tanaka, T., 264
- Sugiyama, M., Patierno, S. R., Cantoni, O., and Costa, M. Characterization of DNA lesions induced by CaCrO_4 in synchronous and asynchronous cultured mammalian cells, 606
- Sugiyama, M., *see* Christie, N. T., 173
- Sundqvist, A., *see* Larsson, A., 614
- Swanson, K. L., Allen, C. N., Aronstam, R. S., Rapoport, H., and Albuquerque, E. X. Molecular mechanisms of the potent and stereospecific nicotinic receptor agonist (+)-anatoxin-a, 250
- Sweetnam, P. M., and Tallman, J. F. Regional difference in brain benzodiazepine receptor carbohydrates, 299
- T**
- Takahashi, J., *see* Inagaki, M., 577
- Takimoto, C. H., Cadman, E. C., and Armstrong, R. D. Precursor-dependent differences in the incorporation of fluorouracil in RNA, 637
- Tallman, J. F., *see* Sweetnam, P. M., 299
- Tanaka, T., Umekawa, H., Saitoh, M., Ishikawa, T., Shin, T., Ito, M., Itoh, H., Kawamatsu, Y., Sugihara, H., and Hidaka, H. Modulation of calmodulin function and of Ca^{2+} -induced smooth muscle contraction by the calmodulin antagonist HT-74, 264
- Tanner, L. I., Harden, T. K., Wells, J. N., and Martin, M. W. Identification of the phosphodiesterase regulated by muscarinic cholinergic receptors of 1231N1 human astrocytoma cells, 455
- Tephly, T. R., Black, K. A., Green, M. D., Coffman, B. L., and Dannan, G. A. Effect of the suicide substrate 3,5-diethoxycarbonyl-2,6-dimethyl-4-ethyl-1,4-dihydropyridine on the metabolism of xenobiotics and on cytochrome P-450 apoproteins, 81
- Thomas, P. E., *see* Wrighton, S. A., 405
- Thurman, R. G., *see* Anundi, I. M., 599
- Thurman, R. G., *see* Harris, C., 88
- Toll, L., *see* Loew, G., 546
- Topiol, S., *see* Weinstein, H., 28
- Tsai, S.-C., *see* Halpern, J. L., 515
- Tseng, H. S., *see* Ueda, I., 582
- Tucker, A. N., Vore, S. J., and Luster, M. I. Suppression of B cell differentiation by 2,3,7,8-tetrachlorodibenzo-*p*-dioxin, 372
- U**
- Ueda, I., *see* Mashimo, T., 149
- Ueda, I., Tseng, H. S., Kaminoh, Y., Ma, S.-M., Kamaya, H., and Lin, S. H. Anesthetics release unfreezable and bound water in partially hydrated phospholipid lamellar systems and elevate phase transition temperature, 582
- Umekawa, H., *see* Tanaka, T., 264
- V**
- Vaughan, M., *see* Halpern, J. L., 515
- Venuti, M. C., *see* Alvarez, R., 554
- Vincent, J.-P., *see* Bozou, J.-C., 489
- von Borstel, R. C., *see* Dickie, P., 427
- Vore, S. J., *see* Tucker, A. N., 372
- W**
- Wang, G. K., *see* Rando, T. A., 467
- Watanabe, Y., and Jakobs, K. H. Inhibition of N_2 -stimulated human

- platelet adenylate cyclase by forskolin, 258
- Watkins, P. B., *see* Wrighton, S. A., 405
- Weinstein, H., Mazurek, A. P., Osman, R., and Topiol, S. Theoretical studies on the activation mechanism of the histamine H₂-receptor: The proton transfer between histamine and a receptor model, 28
- Wells, J. N., *see* Tanner, L. I., 455
- Will, C. L., and Dolnick, B. J. 5-Fluorouracil augmentation of dihydrofolate reductase gene transcripts containing intervening sequences in methotrexate-resistant KB cells, 643
- Williams, M. V. Effects of mercury (II) compounds on the activity of dUTPases from various sources, 288
- Wolfe, S. E., and Brostrom, M. A. Mechanisms of action of inhibitors of prolactin secretion in GH₃ pituitary cells. II. Blockade of voltage-dependent Ca²⁺ channels, 420
- Wolfe, S. E., Brostrom, C. O., and Brostrom, M. A. Mechanisms of action of inhibitors of prolactin secretion in GH₃ pituitary cells. I. Ca²⁺-dependent inhibition of amino acid incorporation, 411
- Wrighton, S. A., Campanile, C., Thomas, P. E., Maines, S. L., Watkins, P. B., Parker, G., Mendez-Picon, G., Haniu, M., Shively, J. E., Levin, W., and Guzelian, P. S. Identification of a human liver cytochrome P-450 homologous to the major isosafrole-inducible cytochrome P-450 in the rat, 405
- Wu, H.-L., *see* Mong, S., 235
- Y**
- Yagaloff, K. A., and Hartig, P. R. Solubilization and characterization of the serotonin 5-HT_{1c} site from pig choroid plexus, 120
- Yang, C.-Z., *see* Recanatini, M., 436
- Z**
- Zahniser, N. R., *see* Cooper, D. F., 113
- Ziegler, D. M., *see* Cashman, J. R., 163
- Zunino, F., *see* Britt, M., 74

SUBJECT INDEX FOR VOLUME 29

A

- Acetaminophen, metabolism, horseradish peroxidase-catalyzed oxidation, 155
- Acetylcholine
binding, kinetics (frog), 250
receptors, *see* Receptors
release, Quinacrine and AH5183 inhibition of, 45
- Adenosine, receptors, *see* Receptors
- Adenylate cyclase
calcium ion-mobilizing hormones and, hepatocytes, 196
cannabinimetic drug inhibition of, G protein and, 307
inhibition
D-2 receptors, 113
forskolin, platelets, 258
inhibitory GTP-binding component, neuroblastoma N1E115 cells, 489
receptor coupling, platelet aggregation desensitization and, 1
- ADP-ribosylation, *N*-ethylmaleimide effects, GTP-binding proteins, 244
- Adrenal medulla, chromaffin cells, catecholamine secretion, α_1 -adrenoceptors and, 134
- α -Adrenergic agonists, protein synthesis and, hepatocytes, 104
- Adrenoceptors, *see* Receptors
- AH5183, Quinacrine and, inhibition of acetylcholine release, 45
- Albumin, bovine serum, surface potential of, inhalation anesthetics and, 149
- Alkylating agent, bioreductive, biochemistry of, 168
- Allylnormetazocine, binding, acetylcholine receptors, *Torpedo*, 179
- Amiloride, calcium and sodium fluxes, heart cells (chick), 363
- Amino acids, conjugates of 1,3-dipropylxanthine, congener approach to, 126
- γ -Aminobutyric acid
agonists and antagonists, after chloride flux, brain membranes (mouse), 497
B receptors, *see* Receptors
- Aminopeptidases, enkephalin-inactivating, 281
- Aminopyrine, metabolism, suicide substrates and, 81
- AMP deaminase, activity, function of rate of cell proliferation, 383
- Amrinone, cGMP-inhibited phosphodiesterase, cardiac muscle, 506
- Anaerobic conditions, paraquate radicals, lung epithelial cells (rabbit), 484
- Anaphylaxis, slow rotating substance of, receptors, lung membranes (guinea pig), 235
- Anatoxin, stereospecificity, potency and (frog), 250
- Anesthesia, theory, 582
- Anesthetics
inhalation
protein surface potential and, 149
theory, 582
local, grating process of neuronal sodium channels and (frog), 467
- Angiotensin-converting enzyme, characterization, [3 H]captopril binding, 142
- Angiotensin II, pertussis toxin and, hepatocytes, 196
- Anthracycline antibiotics, binding to DNA, 74
- Anthraquinone, derivatives, biological effect and DNA binding of, 211
- Antibiotics
anthracycline, binding to DNA, 74
end-plate channels and (snake), 52
polyene macrolide antifungal, ionic permeability and, unilamellar vesicles, 293

- Antitumor agents, potential, DNA binding and, 211
- Aristeromycin, metabolism, mode of action, 383
- Astrocytoma cells
H₁-histamine receptors, 188
phosphodiesterase, regulated by muscarinic cholinergic receptors, 455
- Auranofin, metallothionein gene expression and, mammalian cells, 204

B

- Batrachotoxin, interaction with veratridine, grating process of neuronal sodium channels (frog), 467
- B cells, differentiation, suppression by TCDD, 372
- Benzamidine, quantitative structure-activity relations, inhibition of trypsin, 436
- Benzodiazepine, receptors, *see* Receptors
- Benzomorphans, binding to acetylcholine receptor, *Torpedo*, 179
- Brain
acetylcholine release, AH5183 and Quinacrine effects, 45
benzodiazepine receptor carbohydrates, regional differences in (rat), 299
membranes
chloride flux, γ -aminobutyric acid after (mouse), 497
high affinity binding of nicotine (rat), 448
receptors, *see* Receptors
- Bromocriptine
inhibition of calcium uptake, GH₃ pituitary cells, 420
inhibition of protein synthesis, GH₃ pituitary cells, 411
- α -Bungarotoxin, binding, α -subunit acetylcholine receptor, 649
- Butyrophenone, antibodies, haloperidol binding and, 589

C

- Calcium
binding proteins, smooth muscle contraction, calmodulin effects, 264
cytosolic concentration, forskolin effects, tumor cells (rat), 461
flux, amiloride and ouabain effects, heart cells (chick), 363
immobilization, pertussis toxin effects, hepatocytes, 196
mobilization
receptor control of, muscle cells, 531
receptor regulation, astrocytoma cells, 455
mobilizing hormones, protein synthesis, regulation in hepatocytes, 104
second messenger role, redistribution of gonadotrope protein kinase C (rat), 570
uptake, inhibition by phenothiazines, GH₃ cells, 420
- Calcium channels, voltage-dependent, blockade by secretory inhibitors, GH₃ cells, 420
- Calcium ionophore A23187, smooth muscle contraction and, 264
- Calcium ions, mobilization, astrocytoma cells, 188
- Calmodulin
antagonists, naphthalenesulfonamides as, 577
calcium binding to, smooth muscle contraction and, 264
residue 82-93 of, binding of phenothiazine derivatives to, 355
- Calorimetry, differential scanning, unfreezable water and anesthetics, 582
- Cannabinimetic drugs, adenylate cyclic inhibition by, G protein and, 307
- Captopril, 3 H-labeled, angiotensin converting enzyme effects, 142
- Carbocyclic adenosine analogs, metabolism, mode of action, 383
- Carbohydrates
benzodiazepine receptor, brain, regional differences in (rat), 299

Carbohydrates—continued

- metabolism, NMR studies, *Fasciola hepatica*, 65
- Cardiotonic agents
 - inhibitor of cyclic AMP phosphodiesterase, 554
 - receptor for, 506
- Catecholamines, secretion, adrenal medullary cells, α_2 -adrenoceptors and, 134
- Cation, binding, cytosine guanine interactions, 378
- Cell division cycle, receptor metabolism, synchronous and asynchronous S49 lymphoma cells, 7, 16
- Chloramphenicol
 - analogs, mechanism-based inactivators, liver cytochrome P-450 (rat), 391
 - isomers, end-plate channels and (snake), 52
- Chloride, flux, γ -aminobutyric acid agonists and antagonists after, brain membranes (mouse), 497
- Chlorpromazine, inhibition of protein synthesis, GH₃ pituitary cells, 411
- Choline, transport, AH5183 and Quinacrine effects, 45
- Cholinergic binding site, location, acetylcholine receptor containing, 649
- Choroid plexus, serotonin recognition site (pig), 120
- Chromaffin granule membranes, *meta*-iodobenzylguanidine uptake in, 275
- Chromate, cytotoxicity, DNA alkylation by mitomycin C, 622
- Chromatin, structure, *N*-hydroxyacetamol effects, 478
- Cisplatin, structure-activity relations, 378
- Clonidine, catecholamine secretion and, adrenal medullary cells, 134
- Conformational analysis
 - μ -active, enkephalin analogs, 314
 - haloperidol binding, 589
- Congeners, functionalized approach, adenosine receptor antagonists, 126
- Coral toxin, *see* *Goniopora* toxin
- Cyclic AMP
 - activation of tyrosine hydroxylase, striatum (rat), 561
 - β -adrenergic receptor expression, synchronous and asynchronous S49 lymphoma cells, 7, 16
 - degradation, astrocytoma cells, 188
 - formation, neurotensin-mediated inhibition of, neuroblastoma N1E115 cells, 489
 - pertussis toxin and, hepatocytes, 196
 - phosphodiesterase
 - cardiac muscle, 506
 - potent, selective inhibitor of, 554
 - regulation by muscarinic cholinergic receptors, astrocytoma cells, 455
- Cyclic GMP
 - formation, neurotensin-mediated inhibition of, neuroblastoma N1E115 cells, 489
 - inhibitor of, cardiotonic and antithrombotic properties, 554
- Cycloheximide, adrenergic receptor regulation, BC3H-1 muscle cells, 521
- Cyclooxygenase, inhibition, blood platelets, 39
- N⁶-Cyclopentyladenosine, NECA binding and, striatal membranes (rat), 331
- 8-Cyclopentyltheophylline, NECA binding and, striatal membranes (rat), 331
- Cystathionase, *Eubacterium limosum*, 97
- Cysteine conjugate β -lyase, *Eubacterium limosum*, 97
- Cytochrome P-450
 - apoproteins, suicide substrate effects, 81
 - identification, human liver, 405
 - isozyme 3a, ethanol-inducible, hydroxylation of *p*-nitrophenol by (rabbit), 399
 - liver, chloramphenicol analogs and (rat), 391
- Cytosine, guanine interactions, metal binding, 378
- Cytotoxicity, DNA damage, mammalian cells, 606

D

- Daunorubicin, binding, B and Z DNA, 74
- Deoxyuridine triphosphate nucleotidohydrolases, *see* dUTPases
- Desensitization, epinephrine-induced platelet aggregation, α_2 -adrenergic receptor binding and (human), 1
- Detergent, solubilization, receptors, lung membranes (guinea pig), 235
- 3,5-Diethoxycarbonyl-2,6-dimethyl-4-ethyl-1,4-dihydropyridine, xenobiotic metabolism, cytochrome P-450 apoproteins and, 81
- Digitalis glycosides, inhibition of sodium-potassium-ATPase, 270
- Digitoxigenin, structure and activity, 16 β -substitution effects, 270
- Dihydrofolate reductase, 5-fluorouracil augmentation of, RNA, 643
- Dimyristoylphosphatidylcholine, unfreezable water and anesthetics, 582
- DNA
 - anthelmintic pyrvinium cation binding to, 427
 - B and Z, anthracycline antibiotic binding to, 74
 - drug interaction, potential antitumor agents, 211
 - lesions, induced by CaCrO₄, mammalian cells, 606
 - polymerase, inhibition by triphosphates of guanosine analogs, 614
 - protein crosslinks, alkylation by mitomycin C, 622
 - repair, mercury effects, Chinese hamster ovary cells, 173
 - structure and function, *N*-hydroxyacetamol effects, 478
- Dopamine
 - D-2 receptors, inhibition of adenylate cyclase, 113
 - nerve terminal autoreceptor, tyrosine hydroxylase, striatum (rat), 561
- Doxorubicin, binding, B and Z DNA, 74
- dUTPases, activity, mercury compound effects, 288

E

- Eledoisin, binding sites, conformationally constrained tachykinin analogs, 34
- Enkephalin
 - cyclic analogs, μ -active conformation of, 314
 - inactivation, aminopeptidases, 281
- Epinephrine, platelet aggregation initiated by, desensitization, 1
- Ergotamine
 - inhibition of calcium uptake, GH₃ pituitary cells, 420
 - inhibition of protein synthesis, GH₃ pituitary cells, 411
- Ethanol, induction, *p*-nitrophenol hydroxylation (rabbit), 399
- N*-Ethylmaleimide, GTP-binding protein and, 244
- Eubacterium limosum*, cysteine conjugate β -lyase in, 97

F

- Fasciola hepatica*, carbohydrate metabolism, substrate cycling and, NMR studies, 65
- Fenoximone, cGMP-inhibited phosphodiesterase, cardiac muscle, 506
- Ferrochelataze, suicide substrates and, 81
- Fluorimetric titrations, anthelmintic pyrvinium cation binding, DNA, 427
- Fluoropyrimidines, RNA incorporation, 637
- Fluorouracil
 - dihydrofolate reductase gene transcripts, RNA, 643
 - DNA damage, mammalian cells, 606
 - incorporation, RNA, 637
- Forskolin
 - activation, tyrosine hydroxylase and, striatum (rat), 561
 - adenylate cyclase inhibition, platelets, 258
 - calcium-evoked prolactin release and, tumor cells (rat), 461
- Free radicals
 - acetaminophen, reactions to horseradish peroxidase oxidation, 155
 - paraquat, lung epithelial cell uptake of (rabbit), 484

G

- Gene expression, metallothionein, regulation by gold compounds, mammalian cells, 204

Glutathione

- conjugates, acetaminophen, horseradish peroxidase-catalyzed oxidation of, 155
- sublobular conjugation, liver, 88

Glycosidase treatment, benzodiazepine receptor, brain (rat), 299

Glyoxal, formation, misonidazole reduction, 168

GnRH, *see* Gonadotropin-releasing hormone

Gold compounds, regulation of metallothionein gene expression, mammalian cells, 204

Gonadotropin, release of, calcium influx dependence (rat), 570

Gonadotropin-releasing hormone, protein kinase C, hormone-stimulated redistribution (rat), 570

Goniopora toxin, sodium channels and, neuroblastoma cells (mouse), 347

G proteins, cannabimimetic drugs and, adenylate cyclase inhibition, 307

GRF, *see* Growth hormone-releasing factor

Growth hormone-releasing factor, interaction with vasoactive intestinal peptide receptors, species specificity (human, rat), 23

GSH, *see* Glutathione

GTP, binding protein, *N*-ethylmaleimide effects, 244

Guanine nucleotides

- β -adrenergic response regulation by, synchronous and asynchronous S49 lymphoma cells, 16

- binding protein, lung membranes (guinea pig), 235

- regulatory proteins

- astrocytoma cells, 188

- calcium ion-mobilizing hormones, hepatocytes, 196

Guanosine analogs, triphosphates of, DNA polymerase inhibition by, 614

H

Haloperidol, binding, monoclonal antibodies, 589

Heart cells, calcium and sodium fluxes, amiloride and ouabain effects (chick), 363

Heart muscle, cGMP-inhibited phosphodiesterase, 506

Hepatic microsomes, *p*-nitrophenol, hydroxylation of (rabbit), 399

Hepatocytes

- calcium ion-mobilizing hormones, pertussis toxin and, 196

- protein synthesis in, regulation by calcium-mobilizing hormones, 104

Herpes simplex virus, DNA polymerases, inhibition by triphosphates of guanosine analogs, 614

Histamine, receptors, *see* Receptors

Horseradish peroxidase, oxidation, acetaminophen, 155

HT-74, calcium-induced smooth muscle contraction and, 264

Hydrolysis, sublobular, organic sulfates (rat), 599

N-Hydroxypropylacetamol, DNA structure and function and, 478

I

Indomethacin, high affinity binding sites, blood platelets, 39

Inotropic agents, cyclic AMP phosphodiesterase inhibitors, 554

Intestine, vasoactive peptide receptors, growth hormone-releasing factor interaction with, species specificity (human, rat), 23

meta-Iodobenzylguanidine, uptake, chromaffin granule membranes, 275

Isozyme P-450d, cytochrome, human homolog, 405

L

Leukotriene, receptors, *see* Receptors

Ligand

- irreversible, peripheral benzodiazepine receptors, 540

- receptor, *see* Receptors

Lipid membrane, unfreezable water and anesthetics, 582

Lipids, second messenger role, redistribution of gonadotropin protein kinase C (rat), 570

Liver

- drug metabolism, suicide substrates and, 81

microsomal preparations, MPTP metabolism in, 163

organic sulfate, sublobular hydrolysis (rat), 599

periportal and pericentral regions, glutathione adduct formation in, 88

Lung, epithelial cells, paraquat uptake (rabbit), 484

Luteinizing hormone, release of, calcium influx dependence (rat), 570

β -Lyase, cysteine conjugate, *Eubacterium limosum*, 97

Lymphoma cells, S49, synchronous and asynchronous, β -adrenergic receptor expression in, 7, 16

M

Mechanism-based inactivators, chloramphenicol as, liver cytochrome P-450 (rat), 391

Membrane phase transitions, temperature and, α_2 -receptors of platelets, 228

Mercury, DNA repair and, Chinese hamster ovary cells, 173

Mercury compounds, dUTPase activity and, 288

Metallothionein, gene expression, regulation by gold compounds, mammalian cells, 204

Methotrexate, -resistant KB cells, intron-containing dihydrofolate reductase RNA, 5-fluorouracil augmentation of, 643

3-Methylcholanthrene-inducible family, liver, identification of cytochrome P-450, 405

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, *see* MPTP

4-Methylumbelliferyl sulfate, sublobular hydrolysis with (rat), 599

Milrinone, cGMP-inhibited phosphodiesterase, cardiac muscle, 506

Misonidazole, reduction, NADPH-cytochrome c (P-450) reductase, 168

Mitomycin C, enzyme-activated, DNA alkylation by, 622

Molecular graphics, benzamide, inhibition of trypsin, 436

Monoamine, uptake, chromaffin granule membranes, 275

Monoclonal antibodies, transducin α -subunit, guanyl nucleotide-binding proteins, 515

Morphiceptin analogs, structure-activity studies, 546

Morphine, metabolism, suicide substrates and, 81

Motor end-plate, ion channel block, stereoselectivity (snake), 52

MPTP, metabolism, contribution of *N*-oxygenation to, 163

Muscarinic agonists, inhibition of protein synthesis, GH₃ pituitary cells, 411

Muscle, smooth, calcium-induced contraction, calmodulin function in, 264

Muscle cells

BC3H-1

- adrenergic receptors, agonist-mediated regulation, 521

- receptor control of intracellular calcium, 531

Mutagenic activity, nitrogen, electron affinity and, 629

Myosin light chain kinase, calcium binding to calmodulin and, smooth muscle contraction, 264

N

NADPH-cytochrome c reductase, kinetic action, nitroimidazoles, 168

Naphthalenesulfonamides

- calcium binding to calmodulin and, smooth muscle, 264

- calmodulin antagonists and protein kinase inhibitors, 577

NECA, A₂ adenosine receptor labeled by, striatal membranes (rat), 331

Neplanocin A, metabolism, mode of action, 383

Neuroblastoma cells

- adenylate cyclase inhibition, cannabimimetic drugs, 307

- N1E115, cyclic AMP formation in, neurotensin-mediated inhibition of, 489

- sodium channels, action of polypeptide neurotoxin in (mouse), 347

Neuromuscular junction

- antibiotic interactions, end-plate channels (snake), 52

- nicotinic receptor agonists (frog), 250

Neurotensin, inhibition, cyclic AMP formation, neuroblastoma N1E115 cells, 489

Nicotine

- benzomorphan binding and, acetylcholine receptor, 179

- receptors, *see* Receptors

Nifedipine
 inhibition of calcium uptake, GH₃ pituitary cells, 420
 inhibition of protein synthesis, GH₃ pituitary cells, 411
 Nitrenium ion, mutagenicity, electron affinity and, 629
 Nitroarenes, mutagenicity, electron affinity and, 629
 p-Nitrophenol, hydroxylation of, ethanol-inducible cytochrome P-450 isozyme 3a (rabbit), 399
 Non-steroidal anti-inflammatory drugs, high affinity binding sites, blood platelets, 39
 N proteins, adenylate cyclase, inhibition by forskolin, platelets, 258
 Nuclear magnetic resonance, unilamellar vesicles, ionic permeability of, antibiotic effects, 293
 Nucleotides, cyclic, cannabimimetic drug effects, 307

O

Opiates, benzomorphan, binding to acetylcholine receptor, *Torpedo*, 179
 Opioid peptides, μ -selective, structure-activity studies, 546
 Ouabain, calcium and sodium fluxes, heart cells (chick), 363
 Ovary cells, Chinese hamster, DNA repair, mercury effects, 173
 N-Oxygenation, MPTP, liver preparations, 163

P

Paraquat, uptake, lung epithelial cells (rabbit), 484
 Parasites, carbohydrate metabolism of, NMR studies, *Fasciola hepatica*, 65
 Peptides
 analogs, conformationally constrained, 34
 vasoactive intestinal, receptors, growth hormone-releasing factor interaction with, species specificity (human, rat), 23
 Pertussis toxin
 adenylate cyclase inhibition by cannabimimetic drugs and, 307
 calcium ion-mobilizing hormones and, hepatocytes, 196
 cyclic AMP formation, neurotensin-mediated inhibition, neuroblastoma cells, 489
 Phenothiazines
 calcium binding to calmodulin and, smooth muscle, 264
 derivatives, binding to residues of 82-93 of calmodulin, 355
 inhibition of calcium uptake, GH₃ pituitary cells, 420
 Phenoxybenzamine, adrenergic receptor regulation, BC3H-1 muscle cells, 521
 Phentolamine, α_1 -adrenergic receptor subtypes, brain (rat), 321
 Phenylephrine, smooth muscle contraction and, 264
 2-(4-Phenylpiperidino)cyclohexanol, *see* AH5183
 Phosphodiesterase
 cyclic AMP, inhibitors of, 554
 cGMP-inhibited, cardiac muscle, 506
 Phosphofructokinase, NMR studies, *Fasciola*, 65
 Phosphoinositide, breakdown, receptor regulation, astrocytoma cells, 455
 Pituitary cells
 GH₃
 inhibitors of protein synthesis, 411
 voltage-dependent calcium channels, blockade, 420
 Pituitary gland, hormone release redistribution of gonadotrope protein kinase C (rat), 570
 Platelets
 adenylate cyclase, inhibition by forskolin, 258
 aggregation, epinephrine-initiated, desensitization, 1
 indomethacin, high affinity binding sites for, 39
 α_2 -receptors to, temperature and phase transition effects on ligand binding, 228
 Polyene macrolide antifungal antibiotics, *see* Antibiotics
 Polypeptide neurotoxin, mechanism of action, sodium channels, neuroblastoma cells (mouse), 347
 Polypeptide sequence, α -subunit of acetylcholine receptors, 649
 Potentials, molecular electrostatic, μ -affinity and selectivity, 546

Prazosin, binding, brain (rat), 321
 Prolactin
 calcium-evoked release, forskolin effects, tumor cells (rat), 461
 secretion, inhibitors of, mechanism of action, GH₃ pituitary cells, 411
 Promazine, binding, residues 82-93 of calmodulin, 355
 Promethazine, binding, residues 82-93 of calmodulin, 355
 Protein
 guanine nucleotide-binding, structure and function, 515
 N, adenylate cyclase, inhibition by forskolin, platelets, 39
 phosphorylation, inhibition of, naphthalenesulfonamides and, 577
 surface potential, inhalation anesthetic effects, 149
 synthesis
 hepatocytes, regulation by calcium-mobilizing hormones, 104
 inhibitors of, GH₃ pituitary cells, 411
 N-hydroxyacetamol effects, 478
 potassium-stimulated, calcium dependence, GH₃ cells, 420
 Protein kinase, inhibitors, naphthalenesulfonamides as, 577
 Protein kinase C, redistribution, GnRH (rat), 570
 Proton, transfer, histamine and a receptor model, 28
 Puromycin, enkephalin release and, brain slices, 281
 Pyruvate antibodies, binding, DNA, 427

Q

Quantum chemistry, histamine H₂-receptor, activation mechanism of, 28
 Quinacrine, AH5183 and, inhibition of acetylcholine release, 45

R

Radioiodinated probes, high affinity, α_2 -adrenergic receptor (rat), 219
 Radioligand, binding, platelets, 228
 Receptors
 acetylcholine
 binding of benzomorphan opiate to, *Torpedo*, 179
 α -subunit of, polypeptide sequence within, 649
 adenosine, antagonists, xanthine conjugates as, 126
 adenosine A₂, striatal membranes (rat), 331
 adrenergic, agonist-mediated regulation, muscle cell line, 521
 α_1 -adrenergic
 control of intracellular calcium, muscle cells, 531
 subtypes, brain (rat), 321
 α_2 -adrenergic
 binding, platelet aggregation desensitization and (human), 1
 catecholamine secretion and, adrenal medullary cells, 134
 high affinity radioiodinated probes for (rat), 219
 temperature and membrane phase transition effects, platelets, 228
 β -adrenergic, synchronous and asynchronous S49 lymphoma cells, 7, 16
 Ah, B cells, TCDD effects, 372
 γ -aminobutyric acid B, uncoupling from GTP-binding proteins by N-ethylmaleimide, 244
 anatoxin, binding affinity (frog), 250
 autoreceptors, regulation of tyrosine hydroxylase, striatum (rat), 561
 benzodiazepine
 carbohydrates, brain, regional difference in (rat), 299
 peripheral type, irreversible ligand of, 540
 brain, nicotine, high affinity sites (rat), 448
 dopamine D₂
 inhibition of adenylate cyclase, 113
 tyrosine hydroxylase and, striatum (rat), 561
 H₁, astrocytoma cells and, 188
 H₂, activation mechanism of, 28
 H₁-histamine, control of intracellular calcium, muscle cells, 531
 leukotriene D₄, solubilization of, lung membranes (guinea pig), 235
 ligand, structure-activity relations, 436
 muscarinic cholinergic, phosphodiesterase regulated by, astrocytoma cells, 455

nicotine, binding, high affinity sites, brain membranes (rat), 448
 Reserpine, *meta*-iodobenzylguanidine uptake, chromaffin granule membranes, 275

RNA

fluorouracil incorporation into, 637
 intron-containing dihydrofolate reductase, fluorouracil augmentation of, 643
 processing, precursors, CaCrO₄ damage, mammalian cells, 606
 structure and function, *N*-hydroxyacetamol effects, 478

S

Salmonella typhimurium, nitroarene mutagenicity, electron affinity and, 629
 Scorpion α -toxin, grating process and, neuronal sodium channels (frog), 467
 Serotonin
 action, carbohydrate metabolism, NMR studies, *Fasciola hepatica*, 65
 recognition site, choroid plexus (pig), 120
 S49 lymphoma cells, synchronous and asynchronous, β -adrenergic receptor expression in, 7, 16
 Sodium, flux, amiloride and ouabain effects, heart cells (chick), 363
 Sodium channels
 neuronal, grating process of, batrachotoxin and veratridine effects (frog), 467
 polypeptide neurotoxin action in, neuroblastoma cells (mouse), 347
 Sodium-potassium-ATPase, binding interaction, digitoxigenin, 270
 Spectrophotometry, micro-reflectance, sublobular GSH conjugation, liver, 88
 Stacking interaction, cytosine guanine, cation effects, 378
 Stereoisomers, chloramphenicol, end-plate channels (snake), 52
 Steroids, metabolism, suicide substrate effects, 81
 Striata
 adenosine A₂ receptor (rat), 331
 D-2 dopamine receptors in, inhibition of adenylate cyclase, 113
 Substance P, hexapeptide analogs, conformationally constrained, 34
 Substrates
 cycling, NMR studies, *Fasciola hepatica*, 65
 suicide, xenobiotic metabolism and cytochrome P-450 apoproteins, 81
 Sulfates, organic, sublobular hydrolysis of (rat), 599

T

Tachykinin
 analogs, conformationally constrained, 34
 receptors, *see* Receptors
 TCDD, immunotoxicity, suppression of B cell differentiation by, 372
 Testosterone, metabolism, suicide substrates and, 81
 Tetrabenazine, *meta*-iodobenzylguanidine uptake, chromaffin granule membranes, 275
 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin, *see* TCDD
³-Tetrahydrocannabinol, adenylate cyclase inhibition by, G protein and, 307

Theophylline, analogs, adenosine receptor antagonists, 126
 Thermodynamics, enzyme-inhibitor interactions, captopril binding, 142
 Thiol, formation, cysteine conjugate β -lyase, 97
 Thiorphan, enkephalin release and, brain slices, 281
Torpedo, acetylcholine receptor, α -subunit of, cholinergic binding site, 649
 Transducin, α -subunit of, monoclonal antibodies to, guanyl nucleotide binding proteins, 515
 Trifluoperazine, inhibition of protein synthesis, GH₃ pituitary cells, 411
 Trifluopromazine, binding, residues 82-93 of calmodulin, 355
 Trypsin, inhibition, benzamide, quantity structure-activity relations, 436
 Tumor cells, 7315c, prolactin-secreting, forskolin effects (rat), 461
 Tyrosine hydroxylase, dopamine autoreceptor regulation of, striatum (rat), 561

U

Ultraviolet, DNA repair induced by, mercury effects, Chinese hamster ovary cells, 173
 Unilamellar vesicles, ionic permeability of, polyene macrolide antifungal antibiotic effects, 293

V

Vasoactive intestinal peptide, receptors, growth hormone-releasing factor interaction with, species specificity (human, rat), 23
 Vasodilators, cyclic AMP phosphodiesterase inhibitors, 554
 Vasopressin
 hepatocytes, calcium-mobilizing hormones and, 104
 pertussis toxin and, hepatocytes, 196
 Verapamil
 inhibition of calcium uptake, GH₃ pituitary cells, 420
 inhibition of protein synthesis, GH₃ pituitary cells, 411
 Veratridine, interaction with batrachotoxin, grating process of neuronal sodium channels (frog), 467
 Voltage clamp, end-plate currents (snake), 52

W

Water, unfreezable, anesthetics and, 582
 WB4101, binding, brain (rat), 321

X

Xanthines, conjugates, adenosine receptor antagonists, 126
 Xenobiotics, metabolism, cysteine conjugate β -lyase, 97
 X-ray, DNA repair induced by, mercury effects, Chinese hamster ovary cells, 173

Y

Yohimban diastereoisomers, radioiodinated α_1 -adrenergic receptor ligand and (rat), 219

An important resource for everyone
involved in research on the
metabolism of drugs and chemicals

DRUG METABOLISM AND DISPOSITION

The Biological Fate of Chemicals


Editor: **Vincent G. Zannoni, PhD**, University of Michigan,
Ann Arbor, Michigan

DRUG METABOLISM AND DISPOSITION publishes *in vitro* and *in vivo* experimental results that bring readers significant and original information on xenobiotic metabolism and disposition, including metabolism of all pharmacologic agents or drugs and environmental chemicals, reactants, and preservatives. All papers are referred to ensure a high standard of publication. The areas covered are:

- pharmacokinetics
- pharmacodynamics
- genetic, nutritional, and hormonal factors affecting the biological fate of chemicals
- toxicological consequences of xenobiotic metabolism

This journal should be a standard reference in all pharmacology and toxicology departments. It is also a valuable resource for all medicinal chemists involved in designing drugs and all biochemists involved with drug metabolism.

Bimonthly



YES! Enter my subscription:

Avoid future rate increases and ensure uninterrupted service—enter your multiyear subscription today!

Drug Metabolism and Disposition (bimonthly)

☐ Individual: \$60/yr ☐ Institutions: \$95/yr

(Please add \$10.00 outside the U.S.)

☐ New Subscription ☐ Renewal ☐ 3 yrs ☐ 2 yrs ☐ 1 yr

name

address

city state zip

Payment options:

☐ Check enclosed
☐ VISA

☐ Bill me

☐ MasterCard

☐ American Express

card #

signature/P.O.#

MD residents, please add 5% sales tax. Subscriptions from outside the US and Canada must be prepaid, in US dollars only. Rates valid for orders received before October 31, 1986.

Please allow 10 weeks for delivery of your first issue. Surface mail delivery to countries outside the US may take up to 16 weeks. Airmail rates available upon request. Residents, fellows, interns, and students when requesting the in training rate (to which you are entitled for 3 years), please specify training status and institution.

Rates subject to change without notice.

Williams & Wilkins

P.O. Box 1496
Baltimore, Maryland 21203

266 Fulham Road
London SW10 9EL, England

DMDAD 93774 86



Broad coverage of pharmacology
in a prestigious journal

THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS


Editor: **Eva King Killam, PhD**, School of Medicine, University of California, Davis

JPET is respected the world over as one of the leading research journals in the field of pharmacology. Readers find broad coverage of all aspects of the interactions of chemicals with biological systems, including:

- autonomic pharmacology
- analgesia
- behavioral pharmacology
- cardiovascular pharmacology
- cellular pharmacology
- chemotherapy
- clinical pharmacology
- developmental pharmacology
- drug abuse
- drug metabolism & disposition
- gastrointestinal pharmacology
- immunopharmacology
- neuropharmacology
- pulmonary pharmacology
- renal pharmacology
- toxicology

JPET is valuable reading for academic, industrial and clinical pharmacologists as well as toxicologists. The Journal deserves a place in every pharmaceutical and toxicological research laboratory and pharmacology/toxicology department throughout the world.

Monthly



YES! Enter my subscription:

Avoid future rate increases and ensure uninterrupted service—enter your multiyear subscription today!

The Journal of Pharmacology and Experimental Therapeutics (monthly)

☐ Individual: \$140/yr ☐ Institutions: \$220/yr
(Please add \$30.00 outside the U.S.)

☐ New Subscription ☐ Renewal ☐ 3 yrs ☐ 2 yrs ☐ 1 yr

name _____

address _____

city state zip _____

Payment options:

- ☐ Check enclosed ☐ Bill me
☐ VISA ☐ MasterCard ☐ American Express

card # _____

signature/P.O.# _____

MD residents, please add 5% sales tax. Subscriptions from outside the US and Canada must be prepaid, in US dollars only. Rates valid for orders received before October 31, 1986.

Please allow 10 weeks for delivery of your first issue. Surface mail delivery to countries outside the US may take up to 16 weeks. Airmail rates available upon request. *Residents, fellows, interns, and students*, when requesting the in-training rate (to which you are entitled for 3 years), please specify training status and institution.

Rates subject to change without notice.

Williams & Wilkins

P.O. Box 1496
Baltimore, Maryland 21203

266 Fulham Road
London SW10 9EL, England

PTAD 93775 86



INSTRUCTIONS TO AUTHORS

Molecular Pharmacology will publish the results of investigations that contribute significant new information on drug action or selective toxicity at the molecular level. The term "drug" is defined broadly to include chemicals that selectively modify biological function.

Suitable papers are those that describe applications of the methods of biochemistry, biophysics, genetics, and molecular biology to problems in pharmacology or toxicology. Also suitable are reports of fundamental investigations which, although not concerned directly with drugs, nevertheless provide an immediate basis for further study of the molecular mechanism of drug action. Observations of phenomena that shed no light upon underlying molecular interactions are not appropriate for publication. Comparative studies, such as those involving drug-receptor or drug-enzyme interactions that already have been well characterized in other types of cells or tissues, also are inappropriate for publication unless they contribute significant new insight into mechanisms.

Specific areas of interest include: stereochemical, electronic, and other parameters of drug architecture; conformational analysis of receptors and their function; drug-enzyme and other interactions between drugs and macromolecules; drug effects upon gene replication and transcription and on protein synthesis; mechanism of action of antibiotics and other growth-inhibitory drugs; induction by drugs of changes in macromolecular structure or allosteric transitions; drug-induced alterations in metabolic pathways; effects of hormones and other drugs on cellular regulatory mechanisms; chemical mutagenesis, carcinogenesis, and teratogenesis; pharmacogenetics, idiosyncrasies, and drug allergies; selective toxicity in a single organism or in different species; drug actions on properties and functions of membranes; mechanisms of drug metabolism; distribution and transport of drug molecules between biological compartments.

Page charges. Authors will be billed at the rate of \$30.00 per page after the paper has been published. It is expected that the page charge will be paid if funds are available for that purpose from the author's institution or from the sponsor of this research. Payment of the charge is not a condition for publication. In case of personal financial hardship, page charges will be waived. Neither the editors nor the reviewers will have knowledge as to who has paid the charge, and this payment always will be considered entirely voluntary.

Submission of manuscript. Manuscripts are published in English only and should be sent to **Dr. William A. Catterall, Editor, *Molecular Pharmacology*, Department of Pharmacology, SJ-30, University of Washington, Seattle, Washington 98195, U. S. A.**

The expenses associated with the review of manuscripts submitted to *Molecular Pharmacology* and other ASPET-sponsored journals that are devoted to publishing original research articles have escalated dramatically in recent years because of ever-increasing costs of postage, supplies, and other office expenses, and the growing number of manuscripts submitted for publication. Thus, it has become necessary for ASPET to follow the example of several other scientific societies which have instituted uniform manuscript handling fees. *Therefore, all manuscripts must be accompanied either by a check for \$30 (in U. S. funds drawn on a U. S. bank payable to ASPET) or by a validated purchase order from the authors' institution.* The review process for submitted manuscripts will be delayed until the manuscript handling fee or purchase order is received in the Editor's office. If submission of the manuscript handling fee entails a personal financial hardship to the author(s), the fee will be waived. In that event, the author(s) should submit a request for waiver of the fee when the manuscript is submitted.

Manuscripts should be typewritten double-spaced with ample margins on one side of the paper, 8½ × 11 inches (ca. 215 × 280 mm). Submit four complete copies of the manuscript and four copies of each figure, plus one original drawing or photograph of each figure. Each half-tone figure requires four original drawings or photographs. All pages should be numbered consecutively beginning with the title page. Limit your reference listings to the minimal number required to document the manuscript adequately. In most instances 30 references or fewer should suffice.

Under usual circumstances reviewers will be instructed to return only their comments to the editorial office and to destroy manuscripts after a final decision on their acceptability has been made.

Original drawings and single copies of manuscripts not accepted for publication will be returned to the authors upon request.

It is understood that the manuscripts and the results they contain will not have been published previously and are not being submitted elsewhere. Manuscripts are accepted for review with the understanding that all persons listed as authors have given their approval for the submission of the paper; further, that any person cited as a source of personal communications has approved such citation. Written authorization may be required at the Editor's discretion. Articles and any other material published in *Molecular Pharmacology* represent the opinions of the author(s) and should not be construed to reflect the opinions of the Editor(s) and the Publisher. If and when a manuscript is published, it will become the sole property of the Journal.

Authors submitting a manuscript do so on the understanding that if it is accepted for publication, copyright in the article, including the right to reproduce the article in all forms and media, shall be assigned exclusively to the Society for Pharmacology and Experimental Therapeutics. No reasonable request by the author for permission to reproduce any of his or her contributions to the journal will be refused.

Organization and style of manuscripts. The policy of the Journal is to allow authors maximum freedom in organizing and presenting their material, and in expressing their ideas, provided only that clarity and conciseness are achieved. For most manuscripts, the most suitable format is: (1) Summary, (2) Introduction, (3) Materials and Methods, (4) Results, and (5) Discussion.

Certain conventions must be observed. Chemical and mathematical formulas and abbreviations should follow the *Instructions to Authors of the Journal of Biological Chemistry* (Vol. 261, pp. 1-11, January 10, 1986). Drugs must be referred to by their generic or chemical names throughout the text, but may be identified by trade name in parentheses or a footnote. The systematic name and number given by the Commission on Enzymes of the International Union of Biochemistry should be included for each enzyme of importance in a paper, at the point in the Summary or Introduction where the enzyme is first mentioned. The use of abbreviations should be minimized and abbreviations avoided in the Summary. All essential abbreviations should be defined in a single footnote when first introduced. Abbreviations of journal names should conform to the style of *Biological Abstracts*. References to papers that

have been accepted for publication, but have not appeared, should be cited like other references with the abbreviated name of the journal followed by the words "in press." Copies of such papers should be sent whenever the findings described in them have a direct bearing on the paper being submitted for publication. "Personal Communications" and "Unpublished Observations" should be cited in footnotes to the text and should not be included in the reference list.

A manuscript should include the following, in the order listed: (1) Title. Numbered footnotes to the title should be avoided; acknowledgment of financial support should be given in an unnumbered footnote to the title. (2) Names of authors, their laboratory and institution. (3) A running title, not exceeding 60 characters and spaces. (4) Summary. (5) Text. Footnotes should be referred to by superscript numbers and references by numbers in parentheses. (6) References, numbered according to order of citation in the text, including title and complete pagination. Examples: 1. Goren, J. H., L. G. Baucé, and W. Vale. Forces and structural limitations of binding of thyrotropin-releasing receptor: the pyroglutamic acid moiety. *Mol. Pharmacol.* 13:606-614 (1977). 2. Chernow, B., and J. T. O'Brian. Overview of catecholamines in selected endocrine systems, in *Norepinephrine* (M. G. Ziegler and C. R. Lake, eds.). Williams and Wilkins, Baltimore, 439-449 (1984). 3. Snedecor, G. W., and W. G. Cochran. *Statistical Methods*. Iowa State University Press, Ames (1967). (7) Footnotes, numbered according to order of appearance in the text. (8) Tables. (9) Figures. (10) Legends to figures. (11) Name and address of person to receive galley proof.

Tables. These should be numbered with arabic numerals and designed to fit the single-column width of the full-page width. Every table should have an explanatory title and sufficient experimental detail in a paragraph following the title to be intelligible without references to the text (unless the procedure is given in the Methods section, or under another table or figure). Footnotes to tables should

appear beneath the tables themselves and should be designated by lower-case italic superscript letters, *a*, *b*, *c*, etc.

Figures. These should be numbered with arabic numerals. Each of the four manuscript copies should contain all of the figures. Only the original set need be of quality suitable for reproduction except in the case of half-tones, which require four sets of photographs or original drawings. These should be unmounted glossy photographs (or original India-ink drawings). Usually figures will be reduced to one column width (85 mm) and all numbers *after* such reduction should be at least 1.5 mm high. The figures must be ready, in all respects, for direct reproduction: no lettering or other art work will be done by the publisher. If symbols are not explained on the face of the figure, only standard characters, of which the printer has type, may be used (×, ○, ●, □, ■, △, ▲, ⊙). The back of each photograph should bear its number, and the legend TOP at the appropriate edge. The list of legends for the figures should give captions and sufficient experimental detail, as required for tables.

Page proof. Authors will be billed for substantial changes in page proof. The Editors are very much interested in having accepted contributions appear in the earliest possible issue of the Journal, and therefore request that galley proof be returned within 24 hours after its receipt. In exceptional cases, a "Note added in proof" may be attached and will be published if the Editor approves.

Reprints and page charges. An order form for reprints as well as information on the estimation of page charges will be mailed with galley proof. Please direct questions on reprints, page charges, or other business matters to Kay Croker, Executive Officer, American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, Md. 20814. Telephone (301)530-7060.